Puma Biotechnology (PBYI) Cash from Investing Activities (2011 - 2026)

Puma Biotechnology has reported Cash from Investing Activities for 16 years, with the latest figure at $2.5 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Investing Activities rose 61.59% year-over-year to $2.5 million; the trailing twelve-month figure through Mar 2026 stood at -$35.2 million (down 20472.83% YoY), and the FY2025 full-year result was -$36.2 million, down 77.06% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at $2.5 million, up from -$27.0 million in the prior quarter.
• The five-year high for Cash from Investing Activities was $11.2 million in Q3 2023, with the low at -$27.0 million in Q4 2025.
• Historically, Cash from Investing Activities has averaged -$3.9 million across 5 years, with a median of $259000.0 in 2024.
• Annual changes were most pronounced in 2022 — Cash from Investing Activities surged 278.93% — and 2025, when it sank 1700.0%.
• Puma Biotechnology's Cash from Investing Activities stood at -$11.9 million in 2022, then surged by 31.19% to -$8.2 million in 2023, then surged by 71.6% to -$2.3 million in 2024, then slumped by 1062.8% to -$27.0 million in 2025, then soared by 109.17% to $2.5 million in 2026.
• The last three Cash from Investing Activities figures came in at $2.5 million (Q1 2026), -$27.0 million (Q4 2025), and $506000.0 (Q3 2025), per Business Quant data.